Naling Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naling Song has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Honglin Gao
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Science, Tianjin 300192, P.R. China
2 shared publicationsYumei Hao
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Science, Tianjin 300192, P.R. China
2 shared publicationsAimin Meng
Department of Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China
1 shared publicationDeguan Li
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Science, Tianjin 300192, P.R. China
1 shared publicationJianfeng Liu
Department of Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China
1 shared publication- Jianfeng Liu
State Key Laboratory of Advanced Medical Materials and Devices Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine Tianjin Institutes of Health Science, Institute of Radiation Medicine Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
1 shared publication
Latest Publications
- Open Access
- 4 December 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (2) , 1149-1154
Targeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cells
The present study aimed to investigate the effects of Na+/H+ exchanger regulatory factor 1 (NHERF1) gene knockdown, using short-hairpin RNA (shRNA), on the malignant behaviors of prostate cancer cells. A pSuper.puro NHERF1 shRNA vector was transfected into PC-3M prostate cancer cells using Lipofectamine 2000. Stable cell lines were obtained and NHERF1 knockdown was verified through western blot analysis. MTT assays were then used to measure PC-3M cell proliferation; in addition, cell migration was assessed using a wound healing assay. Flow cytometry was employed in order to determine the effects of NHERF1 knockdown on apoptosis. Expression levels of apoptotic pathway proteins B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein were then determined by western blot analysis. The results demonstrated that shRNA knockdown of NHERF1 significantly suppressed the proliferation of PC-3M cells by >50%. In addition, knockdown of NHERF1 significantly inhibited the migration of PC-3M cells. PC-3M cells harboring NHERF1 shRNA exhibited significantly increased apoptosis, with an ~4-fold increase compared with that of the parental PC-3M cells and cells transfected with an empty vector. Furthermore, the results revealed that knockdown of NHERF1 reduced the protein expression of Bcl-2, although the expression of Bax was unaltered. In conclusion, NHERF1 knockdown using shRNA inhibited the proliferation and migration of PC-3M cells and promoted apoptosis, highlighting the role of NHERF1 in prostate cancer progression.
- 4 December 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (2) , 1149-1154
Open AccessTargeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cells
The present study aimed to investigate the effects of Na+/H+ exchanger regulatory factor 1 (NHERF1) gene knockdown, using short-hairpin RNA (shRNA), on the malignant behaviors of prostate cancer cells. A pSuper.puro NHERF1 shRNA vector was transfected into PC-3M prostate cancer cells using Lipofectamine 2000. Stable cell lines were obtained and NHERF1 knockdown was verified through western blot analysis. MTT assays were then used to measure PC-3M cell proliferation; in addition, cell migration was assessed using a wound healing assay. Flow cytometry was employed in order to determine the effects of NHERF1 knockdown on apoptosis. Expression levels of apoptotic pathway proteins B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein were then determined by western blot analysis. The results demonstrated that shRNA knockdown of NHERF1 significantly suppressed the proliferation of PC-3M cells by >50%. In addition, knockdown of NHERF1 significantly inhibited the migration of PC-3M cells. PC-3M cells harboring NHERF1 shRNA exhibited significantly increased apoptosis, with an ~4-fold increase compared with that of the parental PC-3M cells and cells transfected with an empty vector. Furthermore, the results revealed that knockdown of NHERF1 reduced the protein expression of Bcl-2, although the expression of Bax was unaltered. In conclusion, NHERF1 knockdown using shRNA inhibited the proliferation and migration of PC-3M cells and promoted apoptosis, highlighting the role of NHERF1 in prostate cancer progression.
- Open Access
- 20 September 2014
- Vol. 17 (9) , 674-678
靶向肽在递送siRNA进行肺癌治疗研究中的应用
肺癌被认为是全球发病率最高的一种恶性肿瘤,其对化疗药物不敏感且易产生耐药性,因此增强肺癌药物治疗效果是近年来研究的热点。siRNA是一种小RNA分子,可以沉默与之互补的目标mRNA,是一种基因治疗手段。靶向肽是一类小分子多肽,它可以与siRNA联合使用,利用其与肿瘤表面物质特异性结合发挥靶向作用。联合靶向肽的特异性和siRNA的治疗作用,增加siRNA在靶点位置的聚集,增强沉默效果,可以提高肺癌对药物的敏感性并降低耐药作用,进而增强肺癌治疗效果,为肺癌的靶向治疗提供新的方向和策略。本文将对靶向肽在递送siRNA进行肺癌治疗研究中的应用作一简要综述。
- 20 September 2014
- Vol. 17 (9) , 674-678
Open Access靶向肽在递送siRNA进行肺癌治疗研究中的应用
肺癌被认为是全球发病率最高的一种恶性肿瘤,其对化疗药物不敏感且易产生耐药性,因此增强肺癌药物治疗效果是近年来研究的热点。siRNA是一种小RNA分子,可以沉默与之互补的目标mRNA,是一种基因治疗手段。靶向肽是一类小分子多肽,它可以与siRNA联合使用,利用其与肿瘤表面物质特异性结合发挥靶向作用。联合靶向肽的特异性和siRNA的治疗作用,增加siRNA在靶点位置的聚集,增强沉默效果,可以提高肺癌对药物的敏感性并降低耐药作用,进而增强肺癌治疗效果,为肺癌的靶向治疗提供新的方向和策略。本文将对靶向肽在递送siRNA进行肺癌治疗研究中的应用作一简要综述。
- Open Access
- 1 March 2014
- Vol. 17 (3) , 189-196
99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究
肺癌是一种死亡率极高的恶性肿瘤,针对肺癌的早期诊断和治疗有着重要的意义和价值,本研究旨在探讨羰基锝法标记的肿瘤抑素T7肽用作裸鼠肺癌早期显像剂的初步研究。 采用羰基锝法标记T7肽,薄层色谱法检测99mTc-T7的放化纯度与稳定性,丙酮作展开系统。测定99mTc-T7与NCI-H157细胞的亲和力。研究99mTc-T7于0.5 h、1 h、2 h、4 h、8 h在荷人非小细胞肺腺癌裸鼠体内的生物分布特性,并计算肿瘤(T)与非肿瘤组织(NT)放射性比值。 99mTc对T7肽标记率高,放化纯度达90%以上,不需进一步纯化,体外稳定性好。99mTc-T7与NCI-H157细胞的平衡解离常数为196.1 nM。99mTc-T7在裸鼠体内主要通过内脏器官代谢,血液清除较快,在肿瘤部位有一定程度聚集,肿瘤/肌肉比值随时间延长而增加,可达到5以上,在4 h-8 h之间取值较为理想。99mTc-T7在肺内存在一过性聚集。 99mTc-T7制备方法简便,标记率高,稳定性好,并能在肺癌肿瘤部位聚集,有望用作肺癌SPECT/CT显像剂。
- 1 March 2014
- Vol. 17 (3) , 189-196
Open Access99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究
肺癌是一种死亡率极高的恶性肿瘤,针对肺癌的早期诊断和治疗有着重要的意义和价值,本研究旨在探讨羰基锝法标记的肿瘤抑素T7肽用作裸鼠肺癌早期显像剂的初步研究。 采用羰基锝法标记T7肽,薄层色谱法检测99mTc-T7的放化纯度与稳定性,丙酮作展开系统。测定99mTc-T7与NCI-H157细胞的亲和力。研究99mTc-T7于0.5 h、1 h、2 h、4 h、8 h在荷人非小细胞肺腺癌裸鼠体内的生物分布特性,并计算肿瘤(T)与非肿瘤组织(NT)放射性比值。 99mTc对T7肽标记率高,放化纯度达90%以上,不需进一步纯化,体外稳定性好。99mTc-T7与NCI-H157细胞的平衡解离常数为196.1 nM。99mTc-T7在裸鼠体内主要通过内脏器官代谢,血液清除较快,在肿瘤部位有一定程度聚集,肿瘤/肌肉比值随时间延长而增加,可达到5以上,在4 h-8 h之间取值较为理想。99mTc-T7在肺内存在一过性聚集。 99mTc-T7制备方法简便,标记率高,稳定性好,并能在肺癌肿瘤部位聚集,有望用作肺癌SPECT/CT显像剂。